ZA202304769B - Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer - Google Patents
Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancerInfo
- Publication number
- ZA202304769B ZA202304769B ZA2023/04769A ZA202304769A ZA202304769B ZA 202304769 B ZA202304769 B ZA 202304769B ZA 2023/04769 A ZA2023/04769 A ZA 2023/04769A ZA 202304769 A ZA202304769 A ZA 202304769A ZA 202304769 B ZA202304769 B ZA 202304769B
- Authority
- ZA
- South Africa
- Prior art keywords
- pah
- para
- combination
- aminohippuric acid
- treating cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2020/081143 WO2022096103A1 (en) | 2020-11-05 | 2020-11-05 | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer |
| PCT/EP2021/080822 WO2022096673A1 (en) | 2020-11-05 | 2021-11-05 | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202304769B true ZA202304769B (en) | 2024-10-30 |
Family
ID=73138835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/04769A ZA202304769B (en) | 2020-11-05 | 2023-04-25 | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230414796A1 (https=) |
| EP (1) | EP4065176B1 (https=) |
| JP (1) | JP7531707B2 (https=) |
| KR (1) | KR20230127212A (https=) |
| CN (1) | CN116981487A (https=) |
| AU (1) | AU2021375728A1 (https=) |
| DK (1) | DK4065176T3 (https=) |
| ES (1) | ES2967379T3 (https=) |
| FI (1) | FI4065176T3 (https=) |
| HU (1) | HUE065304T2 (https=) |
| PL (1) | PL4065176T3 (https=) |
| WO (2) | WO2022096103A1 (https=) |
| ZA (1) | ZA202304769B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR2022007815A1 (tr) * | 2022-05-13 | 2023-11-21 | Ege Ueniversitesi Idari Ve Mali Islerdaire Bsk | Yüksek stabi̇li̇teye ve radyoi̇şaretleme veri̇mi̇ne sahi̇p radyofarmasöti̇kler ve bahsedi̇len radyofarmasöti̇kleri̇ i̇çeren teranosti̇k ki̇t |
| CN115212322B (zh) * | 2022-06-01 | 2024-01-16 | 原子高科股份有限公司 | 一种用于放射性药物制备的冻干药盒及其制备方法 |
| TW202540073A (zh) * | 2023-11-30 | 2025-10-16 | 大陸商輻聯科技香港有限公司 | 靶向ｓｓｔｒ受體的放射性化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006176427A (ja) | 2004-12-21 | 2006-07-06 | Geno Membrane:Kk | エストロン３硫酸トランスポーター活性の阻害剤 |
| US20070025910A1 (en) | 2005-07-29 | 2007-02-01 | Norenberg Jeffrey P | Anticancer therapy |
| US20070166774A1 (en) * | 2006-01-17 | 2007-07-19 | Groman Ernest V | Functional immunoassay |
| US20100255117A1 (en) * | 2007-04-06 | 2010-10-07 | The Johns Hopkins University | Methods and compositions for the treatment of cancer |
| AU2012294639B2 (en) | 2011-08-05 | 2017-10-26 | Molecular Insight Pharmaceuticals, Inc. | Radiolabeled prostate specific membrane antigen inhibitors |
| PL2970345T3 (pl) | 2013-03-15 | 2019-12-31 | Cancer Targeted Technology Llc | Znakowane 18F środki do obrazowania PET ukierunkowane na PSMA |
| EP2862857A1 (en) | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP3456700A1 (en) | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CA3060143A1 (en) | 2017-05-24 | 2018-11-29 | Itm Isotopen Technologien Munchen Ag | Novel psma-binding agents and uses thereof |
| WO2020108753A1 (en) | 2018-11-28 | 2020-06-04 | ITM Isotopen Technologien München AG | Novel tumor antigen binding agents and uses thereof |
| WO2020224780A1 (en) * | 2019-05-08 | 2020-11-12 | ITM Isotopen Technologien München AG | Para-aminohippuric acid (pah) as a renal protective substance |
-
2020
- 2020-11-05 WO PCT/EP2020/081143 patent/WO2022096103A1/en not_active Ceased
-
2021
- 2021-11-05 AU AU2021375728A patent/AU2021375728A1/en active Pending
- 2021-11-05 WO PCT/EP2021/080822 patent/WO2022096673A1/en not_active Ceased
- 2021-11-05 JP JP2023527358A patent/JP7531707B2/ja active Active
- 2021-11-05 FI FIEP21810930.4T patent/FI4065176T3/fi active
- 2021-11-05 PL PL21810930.4T patent/PL4065176T3/pl unknown
- 2021-11-05 HU HUE21810930A patent/HUE065304T2/hu unknown
- 2021-11-05 KR KR1020237018786A patent/KR20230127212A/ko active Pending
- 2021-11-05 DK DK21810930.4T patent/DK4065176T3/da active
- 2021-11-05 EP EP21810930.4A patent/EP4065176B1/en active Active
- 2021-11-05 ES ES21810930T patent/ES2967379T3/es active Active
- 2021-11-05 CN CN202180084046.4A patent/CN116981487A/zh active Pending
- 2021-11-05 US US18/035,662 patent/US20230414796A1/en active Pending
-
2023
- 2023-04-25 ZA ZA2023/04769A patent/ZA202304769B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK4065176T3 (da) | 2024-01-02 |
| CA3171718A1 (en) | 2022-05-12 |
| ES2967379T3 (es) | 2024-04-30 |
| AU2021375728A9 (en) | 2024-06-20 |
| PL4065176T3 (pl) | 2024-03-18 |
| KR20230127212A (ko) | 2023-08-31 |
| AU2021375728A1 (en) | 2023-06-15 |
| EP4065176A1 (en) | 2022-10-05 |
| HUE065304T2 (hu) | 2024-05-28 |
| WO2022096103A1 (en) | 2022-05-12 |
| JP7531707B2 (ja) | 2024-08-09 |
| CN116981487A (zh) | 2023-10-31 |
| US20230414796A1 (en) | 2023-12-28 |
| JP2023547689A (ja) | 2023-11-13 |
| WO2022096673A1 (en) | 2022-05-12 |
| EP4065176B1 (en) | 2023-10-11 |
| FI4065176T3 (fi) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202304769B (en) | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| MXPA04004355A (es) | Tratamiento de combinacion que comprende zd6474 y un taxano. | |
| CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
| EA200700686A1 (ru) | Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии | |
| CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
| MX2007003506A (es) | Terapia de combinacion de cancer que comprende azd2171 e imatinib. | |
| MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
| MX2024000674A (es) | Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion. | |
| BRPI0517953A (pt) | uso de zd 6474, ou de um sal farmaceuticamente aceitável do mesmo, e de um antiandrógeno, composição farmacêutica, kit, e, método para a produção de um efeito da redução da permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente | |
| MX2022011171A (es) | Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos. | |
| DK1653964T3 (da) | Cancerkombinationsterapi omfattende AZD2171 og ZD1839 | |
| BRPI0508959A (pt) | uso de azd2171 ou de um sal do mesmo farmaceuticamente aceitável, uso de sal maleato de azd2171 e oxaliplatina, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente | |
| NO20064755L (no) | Kombinasjonsterapi | |
| ZA200600188B (en) | Combination therapy | |
| GB0406445D0 (en) | Combination therapy | |
| MX2024001892A (es) | Una combinacion terapeutica que comprende un antagonista de tigit, un antagonista de pd-1 y uno o varios agentes quimioterapeuticos. | |
| NO20051601L (no) | Kombinasjonsterapi med gemcitabin og zd6126 |